NeoGenomics Q3 Earnings Top Estimates on Clinical Revenue Growth

martes, 28 de octubre de 2025, 7:19 am ET1 min de lectura
NEO--

NeoGenomics, a cancer diagnostics company, has reported Q3 revenue growth, beating estimates. The company provides oncology diagnostic testing and consultative services, including professional interpretation of laboratory test results by licensed physicians. Its segments include Clinical Services and Advanced Diagnostics. Clinical Services consist of clinical cancer testing, interpretation, and consultative services, while Advanced Diagnostics include clinical trials and research, validation laboratory services, and informatics.

NeoGenomics Q3 Earnings Top Estimates on Clinical Revenue Growth

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios